Latham & Watkins Advises Rhythm Pharmaceuticals in its Public Offering

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, has announced the pricing of its public offering of 5 million shares of its common stock at a public offering price of US$30 per share. All of the shares are being offered by Rhythm. In addition, Rhythm has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less the underwriting discount and commission.

Latham & Watkins LLP advised Rhythm Pharmaceuticals in the transaction with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Jennifer Yoon, Emily Henderson, and Nuri Ruzi.